Navigation Links
Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2011 American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting
Date:3/22/2011

avenous use only. A dose of 1000 Units of Cinryze can be administered every 3 or 4 days for routine prophylaxis against angioedema attacks in HAE patients. Cinryze is administered at an injection rate of 1 mL per minute.

About Hereditary Angioedema (HAE)

HAE is a rare, severely debilitating, life-threatening genetic disorder caused by a deficiency of C1 inhibitor, a human plasma protein. This condition is the result of a defect in the gene controlling the synthesis of C1 inhibitor. C1 inhibitor maintains the natural regulation of the contact, complement, and fibrinolytic systems, that when left unregulated, can initiate or perpetuate an attack by consuming the already low levels of endogenous C1 inhibitor in HAE patients. Patients with C1 inhibitor deficiency experience recurrent, unpredictable, debilitating, and potentially life threatening attacks of inflammation affecting the larynx, abdomen, face, extremities and urogenital tract. Patients with HAE experience approximately 20 to 100 days of incapacitation per year. There are estimated to be at least 6,500 people with HAE in the United States.

For more information on HAE, visit the U.S. HAE Association's website at: www.haea.org or the HAEi (International Patient Organization for C1 Inhibitor Deficiencies) at www.haei.org.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.  ViroPharma commercializes Cinryze® (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).  ViroPharma commercializes Vancocin®,
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
2. Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO)
3. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
4. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
5. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
6. Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care
7. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
8. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
9. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
10. iTherX Initiates Phase 1b Study of First-in-Class Hepatitis C Virus Entry Inhibitor ITX-5061
11. N30 Pharmaceuticals to Present S-Nitrosoglutathione Reductase Inhibitor Preclinical Safety Data at 2011 Society of Toxicology 50th Anniversary Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (the "Company") (NASDAQ: CLSN ) today announced ... purchase an aggregate of approximately $15 million of the ... led by a dedicated health care fund. ... investors pursuant to which the Company agreed to sell ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its ... highly sophisticated agro-breeding solutions for plant breeders and researchers, ... board of directors appointed chemistry and pharmaceutical industry expert ... of the board. From 1975 to 2012, ...
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... Nov. 8, 2011 MedBox (Pink Sheets: ... have changed their ticker symbol to MDBX.  The company ... to MedBox. The company is a ... dispensing systems of prescription medicines. The free-standing unit features ...
... 8, 2011 Reportlinker.com announces that a ... its catalogue: European Markets ... http://www.reportlinker.com/p0681077/European-Markets-for-Ophthalmic-Devices-2011-Diagnostic--Invasive.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Ophthalmic_Devices ... interventional ophthalmic device market was valued at ...
Cached Medicine Technology:MedBox Announces Ticker Symbol Change 2European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 2European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 3European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 4European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 5European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 6European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 7European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 8European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 9European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 10European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 11European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 12European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 13European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 14European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 15European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 16European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 17European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 18European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 19European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 20European Markets for Ophthalmic Devices 2011 (Diagnostic & Invasive) 21
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary research ... Kenis in the Institute of Genomic Biology (IGB) ... Urbana-Champaign describe their recent work on subcellular redox ... cell functions including energy metabolism, signaling, and transcriptional ... normal cellular behavior, redox status has been recognized ...
(Date:4/17/2014)... has created a new technology for modifying human ... the body and selectively target cancer and other ... that monitor and modify human physiology is a ... existing technology enabled bioengineers to build such devices ... in a customized fashion. , "The project addressed ...
(Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
(Date:4/17/2014)... off depression among retirees, particularly among those who live ... The Journals of Gerontology, Series B: Psychological Sciences and ... Use and Depression Among Retired Older Adults in the ... that Internet use reduced the probability of a depressed ... , Late-life depression affects between 5 and 10 million ...
(Date:4/17/2014)... therapy improves general blood flow and alleviates muscle ... researchers at the University of Illinois at Chicago. ... print in the Archives of Physical Medicine ... vascular function in people who had not exercised, ... of their level of physical activity. , Improved ...
Breaking Medicine News(10 mins):Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Internet use may cut retirees' depression 2Health News:Massage therapy improves circulation, eases muscle soreness 2
... anti-reservation medicos strike in India, the government on Sunday night ... on quota in central educational institutes// but the students and ... by calling a bandh in Delhi on May 31. ... talks with Federal Minister Oscar Fernandes who followed it up ...
... attractive destination for conducting global clinical trials due to ... trained medical professionals and sophisticated technological infrastructure. // ... valued at Rs 3.1 billion in 2005 and is ... Most of the US and European nations are outsourcing ...
... Scientists in the US have created an artificial penis ... and may one day help treat men with severe ... Atala and colleagues at the Wake Forest Institute for ... new method of tissue engineering, reported the online edition ...
... city of Faisalabad have been affected by contaminated water, an ... victims of water-borne diseases, which broke out as a result ... to further increase as more people are being hospitalized., ... affected area is also underway. , ,'we have taken ...
... resolve of the students against reservations who continue their stir ... students tried to self immolate themselves - one in the ... whom the police described as a vendor, tried immolating himself ... gathered in strength, staged a rally protesting against the government's ...
... Geneva - The new interim head of the World Health ... first time since assuming office // , confirmed that Dr ... resources and the support from the people to continue the ... that he would continue the work of his predecessor Dr ...
Cached Medicine News:Health News:Two Students Try To Self-Immolate As Anti-Quota Stir Continues 2Health News:Two Students Try To Self-Immolate As Anti-Quota Stir Continues 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: